HPRHealth Psychology ResearchTBA2420-8124Health Psychology Research10.52965/001c.38672GeneralHistorical Pathways for Opioid Addiction, Withdrawal with   Traditional and Alternative Treatment Options with Ketamine,   Cannabinoids, and Noribogaine: A Narrative Reviewhttps://healthpr.org/journal/HPR/10/4/10.52965/001c.38672N. EdinofAmber,W. WuNatalie,BoninBryce,MouhaffelRama,ViningStephen,GibsonWilliam,M. CornettElyse,S. MurnaneKevin,M. KayeAdam,D. KayeAlan20221042022-10-06Even as prescription opioid dispensing rates have begun to decrease, the use of illicit opioids such as heroin and fentanyl has increased. Thus, the end of the opioid epidemic is not in sight, and treating patients that are addicted to opioids remains of utmost importance. Currently, the primary pharmacotherapies used to treat opioid addiction over the long term are the opioid antagonist naltrexone, the partial-agonist buprenorphine, and the full agonist methadone. Naloxone is an antagonist used to rapidly reverse opioid overdose. While these treatments are well-established and used regularly, the gravity of the opioid epidemic necessitates that all possible avenues of treatment be explored. Therefore, in this narrative review, we analyze current literature regarding use of the alternative medications ketamine, noribogaine, and cannabinoids in treating patients suffering from opioid use disorder. Beyond its use as an anesthetic, ketamine has been shown to have many applications in several medical specialties. Of particular interest to the subject at hand, ketamine is promising in treating individuals addicted to opioids, alcohol, and cocaine. Therapeutically administered cannabinoids have been proposed for the treatment of multiple illnesses. These include, but are not limited to epilepsy, Parkinson’s disease, multiple sclerosis, chronic pain conditions, anxiety disorders, and addiction. The cannabinoid dronabinol has been seen to have varying effects. High doses appear to reduce withdrawal symptoms but this comes at the expense of increased adverse side effects such as sedation and tachycardia. Noribogaine is a weak MOR antagonist and relatively potent KOR agonist, which may explain the clinical anti-addictive effects. More research should be done to assess the viability of these medications for the treatment of OUD and withdrawal.Noribogaine, Ketamine, Cannabinoids, Dronabinol, Opiates, Opioid Use Disorder, Withdrawal

1. Centers for Disease Control and Prevention (CDC). CDC grand rounds: prescription drug overdoses - a U.S. epidemic. MMWR Morb Mortal Wkly Rep. 2012;61(1):10-13. 2. Chen LH, Hedegaard H, Warner M. Drug-poisoning Deaths Involving Opioid Analgesics: United States, 1999-2011. NCHS Data Brief. 2014;(166):1-8. 3. Hedegaard H, Miniño AM, Spencer MR, Warner M. Drug Overdose Deaths in the United States, 1999–2020. NCHS Data Brief. 2021;(426):1-8. doi:10.15620/cdc:112340 4. Advisors WHC of E. The underestimated cost of the opioid crisis. Published online 2017. 5. Azadfard M, Huecker MR, Leaming JM. Opioid Addiction. In: StatPearls. StatPearls Publishing; 2022. Accessed June 24, 2022. http://www.ncbi.nlm.nih.gov/books/NBK448203/ 6. Vadivelu N, Kai AM, Kodumudi V, Sramcik J, Kaye AD. The Opioid Crisis: a Comprehensive Overview. Curr Pain Headache Rep. 2018;22(3):16. doi:10.1007/s11916-018-0670-z 7. Hagemeier NE. Introduction to the opioid epidemic: the economic burden on the healthcare system and impact on quality of life. Am J Manag Care. 2018;24(10 Suppl):S200-S206. 8. U.S. Opioid Dispensing Rate Maps | Drug Overdose | CDC Injury Center. Published March 18, 2022. Accessed June 21, 2022. https://www.cdc.gov/drugoverdose/rxrate-maps/index.html 9. Kolodny A, Courtwright DT, Hwang CS, et al. The prescription opioid and heroin crisis: a public health approach to an epidemic of addiction. Annu Rev Public Health. 2015;36:559-574. doi:10.1146/annurev-publhealth-031914-122957 10. Dyer O. Opioid lawsuits: Sackler family agree final $6bn civil settlement with US states. BMJ. 2022;376:o616. doi:10.1136/bmj.o616 11. Mularski RA, White-Chu F, Overbay D, Miller L, Asch SM, Ganzini L. Measuring Pain as the 5th Vital Sign Does Not Improve Quality of Pain Management. J Gen Intern Med. 2006;21(6):607-612. doi:10.1111/j.1525-1497.2006.00415.x 12. DSM 5 criteria for Opioid Use Disorder. DSM 5 criteria for Opioid Use Disorder. Accessed July 3, 2022. https://www.asam.org/docs/default-source/education-docs/dsm-5-dx-oud-8-28-2017.pdf 13. Pergolizzi JV Jr, Raffa RB, Rosenblatt MH. Opioid withdrawal symptoms, a consequence of chronic opioid use and opioid use disorder: Current understanding and approaches to management. J Clin Pharm Ther. 2020;45(5):892-903. doi:10.1111/jcpt.13114 14. Wang SC, Chen YC, Lee CH, Cheng CM. Opioid Addiction, Genetic Susceptibility, and Medical Treatments: A Review. Int J Mol Sci. 2019;20(17):4294. doi:10.3390/ijms20174294 15. Piazza PV, Deroche-Gamonet V. A multistep general theory of transition to addiction. Psychopharmacology (Berl). 2013;229(3):387-413. doi:10.1007/s00213-013-3224-4 16. Koob GF. Negative reinforcement in drug addiction: the darkness within. Curr Opin Neurobiol. 2013;23(4):559-563. doi:10.1016/j.conb.2013.03.011 17. Schwartz RP, Kelly SM, O’Grady KE, et al. In-treatment vs. out-of-treatment opioid dependent adults: drug use and criminal history. Am J Drug Alcohol Abuse. 2008;34(1):17-28. doi:10.1080/00952990701653826 18. Tsuang MT, Lyons MJ, Meyer JM, et al. Co-occurrence of abuse of different drugs in men: the role of drug-specific and shared vulnerabilities. Arch Gen Psychiatry. 1998;55(11):967-972. doi:10.1001/archpsyc.55.11.967 19. Chawarski MC, Hawk K, Edelman EJ, et al. Use of Amphetamine-Type Stimulants Among Emergency Department Patients With Untreated Opioid Use Disorder. Ann Emerg Med. 2020;76(6):782-787. doi:10.1016/j.annemergmed.2020.06.046 20. Salsitz E, Wiegand T. Pharmacotherapy of Opioid Addiction: “Putting a Real Face on a False Demon.” J Med Toxicol. 2016;12(1):58-63. doi:10.1007/s13181-015-0517-5 21. Wang S. Historical Review: Opiate Addiction and Opioid Receptors. Cell Transplant. 2019;28(3):233-238. doi:10.1177/0963689718811060 22. Mattick RP, Breen C, Kimber J, Davoli M. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev. 2014;(2):CD002207. doi:10.1002/14651858.cd002207.pub4 23. Sharma B, Bruner A, Barnett G, Fishman M. Opioid Use Disorders. Child Adolesc Psychiatr Clin N Am. 2016;25(3):473-487. doi:10.1016/j.chc.2016.03.002 24. Bhalla S, Andurkar SV, Gulati A. Neurobiology of opioid withdrawal: Role of the endothelin system. Life Sci. 2016;159:34-42. doi:10.1016/j.lfs.2016.01.016 25. McElrath K, Joseph H. Medication-Assisted Treatment (MAT) for Opioid Addiction: Introduction to the Special Issue. Substance Use & Misuse. 2017;53(2):177-180. doi:10.1080/10826084.2017.1404106 26. Kreek MJ, Levran O, Reed B, Schlussman SD, Zhou Y, Butelman ER. Opiate addiction and cocaine addiction: underlying molecular neurobiology and genetics. J Clin Invest. 2012;122(10):3387-3393. doi:10.1172/jci60390 27. Webster LR. Risk Factors for Opioid-Use Disorder and Overdose. Anesth Analg. 2017;125(5):1741-1748. doi:10.1213/ane.0000000000002496 28. Kreek MJ, Reed B, Butelman ER. Current status of opioid addiction treatment and related preclinical research. Sci Adv. 2019;5(10):eaax9140. doi:10.1126/sciadv.aax9140 29. Kosten TR, Baxter LE. Review article: Effective management of opioid withdrawal symptoms: A gateway to opioid dependence treatment. Am J Addict. 2019;28(2):55-62. doi:10.1111/ajad.12862 30. Srivastava AB, Mariani JJ, Levin FR. New directions in the treatment of opioid withdrawal. Lancet. 2020;395(10241):1938-1948. doi:10.1016/s0140-6736(20)30852-7 31. Tisdale JE, Chung MK, Campbell KB, et al. Drug-Induced Arrhythmias: A Scientific Statement From the American Heart Association. Circulation. 2020;142(15):e214-e233. doi:10.1161/cir.000000000000905 32. Whelan PJ, Remski K. Buprenorphine vs methadone treatment: A review of evidence in both developed and developing worlds. J Neurosci Rural Pract. 2012;3(1):45-50. doi:10.4103/0976-3147.91934 33. Sigmon SC, Bisaga A, Nunes EV, O’Connor PG, Kosten T, Woody G. Opioid detoxification and naltrexone induction strategies: recommendations for clinical practice. Am J Drug Alcohol Abuse. 2012;38(3):187-199. doi:10.3109/00952990.2011.653426 34. Mion G, Villevieille T. Ketamine pharmacology: an update (pharmacodynamics and molecular aspects, recent findings). CNS Neurosci Ther. 2013;19(6):370-380. doi:10.1111/cns.12099 35. Dundee JW, Bovill J, Knox JWD, et al. Ketamine as an induction agent in anaesthetics. Lancet. 1970;295(7661):1370-1371. doi:10.1016/s0140-6736(70)91273-0 36. Zanos P, Moaddel R, Morris PJ, et al. Ketamine and Ketamine Metabolite Pharmacology: Insights into Therapeutic Mechanisms. Pharmacol Rev. 2018;70(3):621-660. doi:10.1124/pr.117.015198 37. Morgan CJA, Curran HV, Independent Scientific Committee on Drugs. Ketamine use: a review. Addict Abingdon Engl. 2012;107(1):27-38. doi:10.1111/j.1360-0443.2011.03576.x 38. Nowacka A, Borczyk M. Ketamine applications beyond anesthesia – A literature review. Eur J Pharmacol. 2019;860:172547. doi:10.1016/j.ejphar.2019.172547 39. Curran HV, Morgan C. Cognitive, dissociative and psychotogenic effects of ketamine in recreational users on the night of drug use and 3 days later. Addict Abingdon Engl. 2000;95(4):575-590. doi:10.1046/j.1360-0443.2000.9545759.x 40. Rao LK, Flaker AM, Friedel CC, Kharasch ED. Role of Cytochrome P4502B6 Polymorphisms in Ketamine Metabolism and Clearance. Anesthesiology. 2016;125(6):1103-1112. doi:10.1097/aln.000000000001392 41. Franks NP, Lieb WR. Molecular and cellular mechanisms of general anaesthesia. Nature. 1994;367(6464):607-614. doi:10.1038/367607a0 42. Dilmore JG, Johnson JW. Open channel block and alteration of N-methyl-D-aspartic acid receptor gating by an analog of phencyclidine. Biophys J. 1998;75(4):1801-1816. doi:10.1016/s0006-3495(98)77622-2 43. Kohrs R, Durieux ME. Ketamine: teaching an old drug new tricks. Anesth Analg. 1998;87(5):1186-1193. doi:10.1097/00000539-199811000-00039 44. Udesky JO, Spence NZ, Achiel R, Lee C, Flood P. The role of nicotinic inhibition in ketamine-induced behavior. Anesth Analg. 2005;101(2):407-411. doi:10.1213/01.ane.0000155291.81338.90 45. Pacheco D da F, Romero TRL, Duarte IDG. Central antinociception induced by ketamine is mediated by endogenous opioids and μ- and δ-opioid receptors. Brain Res. 2014;1562:69-75. doi:10.1016/j.brainres.2014.03.026 46. Domino EF, Chodoff P, Corssen G. Pharmacologic effects of CI-581, a new dissociative anesthetic, in man. Clin Pharmacol Ther. 1965;6(3):279-291. doi:10.1002/cpt196563279 47. Serafini G, Howland R, Rovedi F, Girardi P, Amore M. The Role of Ketamine in Treatment-Resistant Depression: A Systematic Review. Curr Neuropharmacol. 2014;12(5):444-461. doi:10.2174/1570159x12666140619204251 48. Loo CK, Gálvez V, O’Keefe E, et al. Placebo-controlled pilot trial testing dose titration and intravenous, intramuscular and subcutaneous routes for ketamine in depression. Acta Psychiatr Scand. 2016;134(1):48-56. doi:10.1111/acps.12572 49. Reinstatler L, Youssef NA. Ketamine as a potential treatment for suicidal ideation: a systematic review of the literature. Drugs R D. 2015;15(1):37-43. doi:10.1007/s40268-015-0081-0 50. Zhou X, Zhang P, Luo W, et al. Ketamine induces apoptosis in lung adenocarcinoma cells by regulating the expression of CD69. Cancer Med. 2018;7(3):788-795. doi:10.1002/cam4.1288 51. Malsy M, Gebhardt K, Gruber M, Wiese C, Graf B, Bundscherer A. Effects of ketamine, s-ketamine, and MK 801 on proliferation, apoptosis, and necrosis in pancreatic cancer cells. BMC Anesthesiol. 2015;15:111. doi:10.1186/s12871-015-0076-y 52. Krupitsky EM, Burakov AM, Dunaevsky IV, Romanova TN, Slavina TY, Grinenko AY. Single versus repeated sessions of ketamine-assisted psychotherapy for people with heroin dependence. J Psychoactive Drugs. 2007;39(1):13-19. doi:10.1080/02791072.2007.10399860 53. Krupitsky EM, Grinenko AY. Ketamine psychedelic therapy (KPT): a review of the results of ten years of research. J Psychoactive Drugs. 1997;29(2):165-183. doi:10.1080/02791072.1997.10400185 54. Dakwar E, Levin F, Foltin RW, Nunes EV, Hart CL. The effects of subanesthetic ketamine infusions on motivation to quit and cue-induced craving in cocaine-dependent research volunteers. Biol Psychiatry. 2014;76(1):40-46. doi:10.1016/j.biopsych.2013.08.009 55. Zuardi AW. History of cannabis as a medicine: a review. Rev Bras Psiquiatr Sao Paulo Braz 1999. 2006;28(2):153-157. doi:10.1590/s1516-44462006000200015 56. Cohen K, Weizman A, Weinstein A. Positive and Negative Effects of Cannabis and Cannabinoids on Health. Clin Pharmacol Ther. 2019;105(5):1139-1147. doi:10.1002/cpt.1381 57. D’Souza DC, Perry E, MacDougall L, et al. The psychotomimetic effects of intravenous delta-9-tetrahydrocannabinol in healthy individuals: implications for psychosis. Neuropsychopharmacol Off Publ Am Coll Neuropsychopharmacol. 2004;29(8):1558-1572. doi:10.1038/sj.npp.1300496 58. Thomas G, Kloner RA, Rezkalla S. Adverse cardiovascular, cerebrovascular, and peripheral vascular effects of marijuana inhalation: what cardiologists need to know. Am J Cardiol. 2014;113(1):187-190. doi:10.1016/j.amjcard.2013.09.042 59. Fraguas-Sánchez AI, Torres-Suárez AI. Medical Use of Cannabinoids. Drugs. 2018;78(16):1665-1703. doi:10.1007/s40265-018-0996-1 60. Console-Bram L, Marcu J, Abood ME. Cannabinoid receptors: nomenclature and pharmacological principles. Prog Neuropsychopharmacol Biol Psychiatry. 2012;38(1):4-15. doi:10.1016/j.pnpbp.2012.02.009 61. Porter BE, Jacobson C. Report of a parent survey of cannabidiol-enriched cannabis use in pediatric treatment-resistant epilepsy. Epilepsy Behav EB. 2013;29(3):574-577. doi:10.1016/j.yebeh.2013.08.037 62. Chagas MHN, Zuardi AW, Tumas V, et al Effects of cannabidiol in the treatment of patients with Parkinson’s disease: an exploratory double-blind trial. J Psychopharmacol Oxf Engl. 2014;28(11):1088-1098. doi:10.1177/0269881114550355 63. Müller-Vahl KR, Schneider U, Koblenz A, et al. Treatment of Tourette’s syndrome with Delta 9-tetrahydrocannabinol (THC): a randomized crossover trial. Pharmacopsychiatry. 2002;35(2):57-61. doi:10.1055/s-2002-25028 64. Newmeyer MN, Swortwood MJ, Barnes AJ, Abulseoud OA, Scheidweiler KB, Huestis MA. Free and Glucuronide Whole Blood Cannabinoids’ Pharmacokinetics after Controlled Smoked, Vaporized, and Oral Cannabis Administration in Frequent and Occasional Cannabis Users: Identification of Recent Cannabis Intake. Clin Chem. 2016;62(12):1579-1592. doi:10.1373/clinchem.2016.263475 65. Grotenhermen F. Pharmacokinetics and pharmacodynamics of cannabinoids. Clin Pharmacokinet. 2003;42(4):327-360. doi:10.2165/00003288-200342040-00003 66. Lucas CJ, Galettis P, Schneider J. The pharmacokinetics and the pharmacodynamics of cannabinoids. Br J Clin Pharmacol. 2018;84(11):2477-2482. doi:10.1111/bcp.13710 67. Devinsky O, Cilio MR, Cross H, et al. Cannabidiol: pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders. Epilepsia. 2014;55(6):791-802. doi:10.1111/epi.12631 68. Schwope DM, Karschner EL, Gorelick DA, Huestis MA. Identification of recent cannabis use: whole-blood and plasma free and glucuronidated cannabinoid pharmacokinetics following controlled smoked cannabis administration. Clin Chem. 2011;57(10):1406-1414. doi:10.1373/clinchem.2011.171777 69. Gaston TE, Friedman D. Pharmacology of cannabinoids in the treatment of epilepsy. Epilepsy Behav EB. 2017;70(Pt B):313-318. doi:10.1016/j.yebeh.2016.11.016 70. Pertwee RG. The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin. Br J Pharmacol. 2008;153(2):199-215. doi:10.1038/sj.bjp.0707442 71. Maillet EL, Milon N, Heghinian MD, et al. Noribogaine is a G-protein biased κ-opioid receptor agonist. Neuropharmacology. 2015;99:675-688. doi:10.1016/j.neuropharm.2015.08.032 72. Corkery JM. Chapter 8 - Ibogaine as a treatment for substance misuse: Potential benefits and practical dangers. In: Calvey T, ed. Progress in Brain Research. Vol 242. Psychedelic Neuroscience. Elsevier; 2018:217-257. doi:10.1016/bs.pbr.2018.08.005 73. Ehrich JM, Messinger DI, Knakal CR, et al. Kappa Opioid Receptor-Induced Aversion Requires p38 MAPK Activation in VTA Dopamine Neurons. J Neurosci. 2015;35(37):12917-12931. doi:10.1523/jneurosci.2444-15.2015 74. Krupitsky E, Burakov A, Romanova T, Dunaevsky I, Strassman R, Grinenko A. Ketamine psychotherapy for heroin addiction: immediate effects and two-year follow-up. J Subst Abuse Treat. 2002;23(4):273-283. doi:10.1016/s0740-5472(02)00275-1 75. Alper KR, Lotsof HS, Frenken GM, Luciano DJ, Bastiaans J. Treatment of acute opioid withdrawal with ibogaine. Am J Addict. 1999;8(3):234-242. doi:10.1080/105504999305848 76. Brown TK, Alper K. Treatment of opioid use disorder with ibogaine: detoxification and drug use outcomes. Am J Drug Alcohol Abuse. 2018;44(1):24-36. doi:10.1080/00952990.2017.1320802 77. Handelsman L, Cochrane KJ, Aronson MJ, Ness R, Rubinstein KJ, Kanof PD. Two new rating scales for opiate withdrawal. Am J Drug Alcohol Abuse. 1987;13(3):293-308. doi:10.3109/00952998709001515 78. Cacciola JS, Alterman AI, McLellan AT, Lin YT, Lynch KG. Initial evidence for the reliability and validity of a “Lite” version of the Addiction Severity Index. Drug Alcohol Depend. 2007;87(2-3):297-302. doi:10.1016/j.drugalcdep.2006.09.002 79. Discontinuation of Buprenorphine Maintenance Therapy: Perspectives and Outcomes - PMC. Accessed July 3, 2022. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4382404/ 80. Amato L, Davoli M, Minozzi S, Ferroni E, Ali R, Ferri M. Methadone at tapered doses for the management of opioid withdrawal. Cochrane Database Syst Rev. 2013;(2):CD003409. doi:10.1002/14651858.cd003409.pub4 81. Mash DC, Ameer B, Prou D, Howes JF, Maillet EL. Oral noribogaine shows high brain uptake and anti-withdrawal effects not associated with place preference in rodents. J Psychopharmacol Oxf Engl. 2016;30(7):688-697. doi:10.1177/0269881116641331 82. Yamaguchi T, Hagiwara Y, Tanaka H, et al. Endogenous cannabinoid, 2-arachidonoylglycerol, attenuates naloxone-precipitated withdrawal signs in morphine-dependent mice. Mol Brain Res. 2001;909(1-2):121-126. doi:10.1016/s0006-8993(01)02655-5 83. Vela G, Ruiz-Gayo M, Fuentes JA. Anandamide decreases naloxone-precipitated withdrawal signs in mice chronically treated with morphine. Neuropharmacology. 1995;34(6):665-668. doi:10.1016/0028-3908(95)00032-2 84. Opioid and Cannabinoid Modulation of Precipitated Withdrawal in Δ9-Tetrahydrocannabinol and Morphine-Dependent Mice | Journal of Pharmacology and Experimental Therapeutics. Accessed July 3, 2022. https://jpet.aspetjournals.org/content/298/3/1007/tab-article-info 85. Wills KL, Parker LA. Effect of Pharmacological Modulation of the Endocannabinoid System on Opiate Withdrawal: A Review of the Preclinical Animal Literature. Front Pharmacol. 2016;7:187. doi:10.3389/fphar.2016.00187 86. Bisaga A, Sullivan MA, Glass A, et al. THE EFFECTS OF DRONABINOL DURING DETOXIFICATION AND THE INITIATION OF TREATMENT WITH EXTENDED RELEASE NALTREXONE. Drug Alcohol Depend. 2015;154:38-45. doi:10.1016/j.drugalcdep.2015.05.013 87. Lofwall MR, Babalonis S, Nuzzo PA, Elayi SC, Walsh SL. Opioid withdrawal suppression efficacy of oral dronabinol in opioid dependent humans. Drug Alcohol Depend. 2016;164:143-150. doi:10.1016/j.drugalcdep.2016.05.002